Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Renner, W; Langsenlehner, U; Krenn-Pilko, S; Eder, P; Langsenlehner, T.
BCL2 genotypes and prostate cancer survival.
Strahlenther Onkol. 2017; 193(6):466-471
Doi: 10.1007/s00066-017-1126-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Renner Wilfried
- Co-Autor*innen der Med Uni Graz
- Krenn-Pilko Sabine
- Langsenlehner Tanja
- Langsenlehner Uwe
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The antiapoptotic B‑cell lymphoma 2 (BCL2) gene is a key player in cancer development and progression. A functional single-nucleotide polymorphism (c.-938C>A, rs2279115) in the inhibitory P2 BCL2 gene promoter has been associated with clinical outcomes in various types of cancer. Aim of the present study was to analyze the role of BCL2-938C>A genotypes in prostate cancer mortality. The association between BCL2-938C>A (rs2279115) genotypes and prostate cancer outcome was studied within the prospective PROCAGENE study comprising 702 prostate cancer patients. During a median follow-up time of 92 months, 120 (17.1%) patients died. A univariate Cox regression model showed a significant association of the CC genotype with reduced cancer-specific survival (CSS; hazard ratio, HR, 2.13, 95% confidence interval, CI, 1.10-4.12; p = 0.024) and overall survival (OS; HR 2.34, 95% CI 1.58-3.47; p < 0.001). In a multivariate Cox regression model including age at diagnosis, risk group, and androgen deprivation therapy, the CC genotype remained a significant predictor of poor CSS (HR 2.05, 95% CI 1.05-3.99; p = 0.034) and OS (HR 2.25, 95% CI 1.51-3.36; p < 0.001). This study provides evidence that the homozygous BCL2-938 CC genotype is associated with OS and C in prostate cancer patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Alleles -
- Androgen Antagonists - therapeutic use
- Combined Modality Therapy -
- Follow-Up Studies -
- Genotype -
- Homozygote -
- Humans -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Neoadjuvant Therapy -
- Neoplasm Grading -
- Neoplasm Staging -
- Polymorphism, Single Nucleotide - genetics
- Proportional Hazards Models -
- Prostatic Neoplasms - genetics
- Prostatic Neoplasms - mortality
- Prostatic Neoplasms - pathology
- Prostatic Neoplasms - therapy
- Proto-Oncogene Proteins c-bcl-2 - genetics
- Radiotherapy Dosage -
- Radiotherapy Planning, Computer-Assisted -
- Radiotherapy, Conformal -
- Survival Analysis -
- Find related publications in this database (Keywords)
- Apoptosis
- Genetics
- Polymorphism
- Oncogene
- Radiotherapy